^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | decitabine (DNMT inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents
Published date:
07/07/2021
Excerpt:
...treated with decitabine or azacitidine as a frontline therapy....diagnosis of AML (hazard ratio 2.915), and mutations in NRAS (hazard ratio 4.440) were identified as poor prognostic factors for survival....In conclusion, mutations in RAS pathway-related genes were predictors of a poor response to HMAs. Particularly, mutated NRAS was associated with inferior survival rates.
DOI:
10.1159/000516793
